Detail akcie Sutro Biopharma Rg online

Business Summary: Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sutro Biopharma Inc revenues increased 92% to $90.8M. Net loss decreased 7% to $144.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Development of biopharmaceutical products segment loss decrease of 31% to $120.3M.